Efficacy of naproxen alone or with cinnarizine compared to placebo as an abortive treatment of vestibular migraine: a randomised placebo controlled, double blind study
- Conditions
- Health Condition 1: G438- Other migraine
- Registration Number
- CTRI/2024/01/061262
- Lead Sponsor
- DrJayantee Kalita
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
The patients with migraine having dizziness will be evaluated for Vestibular Migraine. The moderate to severe VM patients will be included from Neurology outpatient service, SGPGI during the year 2023 to 2024. The diagnosis of VM will be based on an international headache society criteria for VM.
The patient with existing hearing problem, neurological findings, structural abnormality on
CT/ MRI, deafness, vestibular transient ischemic attack, hypertension (BP >160/100 mm Hg),
coronary artery disease, hepatic or kidney failure, chronic obstructive airway disease,
malignancy, systemic diseases, vasculitis, on cancer chemotherapy, immune suppressants,
Page 11
migraine prophylactic treatment, pregnancy, lactation, on oral contraceptive drugs, alcohol
(taking >14 drinks per week) or any other addiction, children < 18 years or elderly > 65 years
and those with history of allergy to naproxen or cinnarizine and not willing to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method